Probiotic for irritable bowel syndrome in pediatric patients
A randomized controlled clinical trial
Keywords:
irritable bowel syndrome, children, probioticsAbstract
Background: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder in children. Recently, probiotics have been suggested as a treatment option for gastrointestinal disorders. The most effective species and the most appropriate doses are still unknown.
Objective: The aim of this study was to assess the effects of Lactobacillus GG (LGG) for treating IBS in pediatric patients.
Methods: In a controlled, double blind, randomized trial, patients with IBS diagnosed by Rome III criteria from August 2012 to September 2012 at Dr. Sheikh Hospital, Mashhad University of Medical Sciences, Iran, were assigned to one of two groups, i.e., intervention and control groups. For four weeks, the intervention group received a probiotic in capsule form that contained LGG at a concentration of 1×1010 cfu/ml bacteria. For the same period, the control group received a placebo capsule that had the same shape and color but only contained inulin, which also was present in the LGG capsules. The primary outcome was any change in the severity of the patients’ pain, and we used a five-point Likert scale to evaluate the severity of their pain. Secondary outcomes were ghanges of the functional scale, stool patterns, and associated problems.
Results: Fifty-two patients participated in the study, and 26 patients were assigned randomly to each of the two groups. The severity of the patients’ pain decreased significantly in the intervention group after one, two, three, and four weeks of treatment, as indicated by P-values of 0.01, 0.00, 0.00, and 0.00, respectively. Also, there was significant improvement in the functional scale after two weeks of treatment (P-value ≤ 0.00).
Conclusion: Lactobacillus GG at a concentration of 1×1010 cfu/ml for a period of four weeks can lessen the severity of the patients’ pain and improve the functional scale in patients with irritable bowel syndrome. Probiotics can have therapeutic effects for IBS patients.
Trial registration: The trial is registered at the Iranian Registry of Clinical Trials (http://www.irct.ir/) with IRCT registration number: IRCT201205219825N1.
Funding: All phases of this study were supported by Mashhad University of Medical Sciences, Iran.
References
Drossman DA, Dumitrascu DL. Rome III: New standard for functional gastrointestinal disorders. J
Gastrointestin Liver Dis. 2006; 15(3): 237-41. PMID: 17013448
Ersryd A, Posserud I, Abrahamsson H, Simren M. Subtyping the irritable bowel syndrome by predominant
bowel habit: Rome II versus Rome III. Aliment Pharmacol Ther. 2007; 26(6): 953-61. doi: 10.1111/j.1365- 2036.2007.03422.x. PMID: 17767480
Singh P, Staller K, Barshop K, Dai E, Newman J, Yoon S, et al. Patients with irritable bowel syndrome- diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation. World J
Gastroenterol. 2015; 21(26): 8103-9. doi: 10.3748/wjg.v21.i26.8103. PMID: 26185382, PMCID:
PMCPMC4499353
Iovino P, Tremolaterra F, Boccia G, Miele E, Ruju FM, Staiano A. Irritable bowel syndrome in childhood:
visceral hypersensitivity and psychosocial aspects. Neurogastroenterol Motil. 2009; 21(9): 940-e74. doi:
1111/j.1365-2982.2009.01303.x. PMID: 19368655
Khalesi M. How probiotic reduce symptoms of irritable bowel syndrome?. International Journal of
Pediatrics. 2014; 2(2.1): 29.
Jafari SA, Ahanchian H, Kiani MA, Khakshour A, Noorbakhsh Z, Zamani E, et al. Synbiotic for prevention
of antibiotic-associated diarrhea in children: a randomized clinical trial. International Journal of Pediatrics.
; 2(1): 55-62.
Enck P, Junne F, Klosterhalfen S, Zipfel S, Martens U. Therapy options in irritable bowel syndrome. Eur J
Gastroenterol Hepatol. 2010; 22(12): 1402-11. doi: 10.1097/MEG.0b013e3283405a17. PMID: 21389791
Dai C, Zheng CQ, Jiang M, Ma XY, Jiang LJ. Probiotics and irritable bowel syndrome. World J
Gastroenterol. 2013; 19(36): 5973-80. doi: 10.3748/wjg.v19.i36.5973. PMID: 24106397, PMCID:
PMC3785618
Gawronska A, Dziechciarz P, Horvath A, Szajewska H. A randomized double-blind placebo-controlled
trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther. 2007; 25(2):
-84. doi: 10.1111/j.1365-2036.2006.03175.x. PMID: 17229242
Lazaraki G, Chatzimavroudis G, Katsinelos P. Recent advances in pharmacological treatment of irritable
bowel syndrome. World J Gastroenterol. 2014; 20(27): 8867-85. doi: 10.3748/wjg.v20.i27.8867. PMID:
, PMCID: PMCPMC4112893
Guandalini S, Magazzu G, Chiaro A, La Balestra V, Di Nardo G, Gopalan S, et al. VSL#3 improves
symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled,
double-blind, crossover study. JPGN. 2010; 51(1): 24-30. doi: 10.1097/MPG.0b013e3181ca4d95. PMID:
Martens U, Enck P, Zieseniss E. Probiotic treatment of irritable bowel syndrome in children. Ger Med Sci.
; 8: Doc07. doi: 10.3205/000096. PMID: 20234804, PMCID: PMC2839254
Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, et al. A randomized
controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable
bowel syndrome. Aliment Pharmacol Ther. 2003; 17(7): 895-904. PMID: 12656692
Bucci C, Tremolaterra F, Gallotta S, Fortunato A, Cappello C, Ciacci C, et al. A pilot study on the effect of
a symbiotic mixture in irritable bowel syndrome: an open-label, partially controlled, 6-month extension of a
previously published trial. Tech Coloproctol. 2013; 18(4): 345-53. doi: 10.1007/s10151-013-1055-2.
PMID: 23922211
Dai C, Guandalini S, Zhao DH, Jiang M. Antinociceptive effect of VSL#3 on visceral hypersensitivity in a
rat model of irritable bowel syndrome: a possible action through nitric oxide pathway and enhance barrier
function. Mol Cell Biochem. 2012; 362(1-2): 43-53. doi: 10.1007/s11010-011-1126-5. PMID: 22020749
Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment
of patients with irritable bowel syndrome--a double blind, placebo-controlled, randomized study. Clin Nutr.
; 24(6): 925-31. doi: 10.1016/j.clnu.2005.06.001. PMID: 16051399
Kajander K, Hatakka K, Poussa T, Farkkila M, Korpela R. A probiotic mixture alleviates symptoms in
irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther. 2005;
(5): 387-94. doi: 10.1111/j.1365-2036.2005.02579.x. PMID: 16128676
Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, et al. Efficacy of an
encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J
Gastroenterol. 2006; 101(7): 1581-90. doi: 10.1111/j.1572-0241.2006.00734.x. PMID: 16863564
Horvath A, Dziechciarz P, Szajewska H. Meta-analysis: Lactobacillus rhamnosus GG for abdominal painrelated functional gastrointestinal disorders in childhood. Aliment Pharmacol Ther. 2011; 33(12): 1302-10.
doi: 10.1111/j.1365-2036.2011.04665.x. PMID: 21507030.
Madden JA, Hunter JO. A review of the role of the gut microflora in irritable bowel syndrome and the
effects of probiotics. Br J Nutr. 2002; 88 Suppl 1: S67-72. doi: 10.1079/BJN2002631. PMID: 12215182
Published
Issue
Section
License
Copyright (c) 2020 knowledge kingdom publishing
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
